RedHill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “buy” rating reiterated by analysts at FBR & Co in a research note issued on Thursday.
Separately, Zacks Investment Research cut shares of RedHill Biopharma from a “hold” rating to a “sell” rating in a report on Friday, July 29th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up 3.61% during mid-day trading on Thursday, reaching $13.79. 75,218 shares of the company’s stock were exchanged. RedHill Biopharma has a one year low of $8.10 and a one year high of $16.54. The company’s market capitalization is $175.60 million. The company’s 50-day moving average price is $14.80 and its 200-day moving average price is $12.74.
RedHill Biopharma (NASDAQ:RDHL) last issued its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.52. On average, equities analysts expect that RedHill Biopharma will post ($2.06) earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares during the period. Oppenheimer & Co. Inc. bought a new stake in RedHill Biopharma during the second quarter worth approximately $142,000. Royal Bank of Canada boosted its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares during the period. Finally, Ingalls & Snyder LLC bought a new stake in RedHill Biopharma during the second quarter worth approximately $451,000. Institutional investors own 15.30% of the company’s stock.
About RedHill Biopharma
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.